- In March 2023, Pfizer announced a Phase 3 study evaluating an investigational IL-6 inhibitor for multicentric Castleman disease (MCD)
- In July 2022, Roche partnered with a clinical research organization to accelerate biologics development for lymphoproliferative disorders
- In 2024, South Korea’s health authority approved a new monoclonal antibody therapy indicated for HHV-8 negative Castleman disease cases
